Xiu-Yan Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiu-Yan Wei has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- An-Hua Wang
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
1 shared publication Cungang Wang
Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Shenyang 110016, Peoples R China
1 shared publicationDan Su
Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
1 shared publication- Di Zhou
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China
1 shared publication Feng Li
Department of Clinical Pharmacy, Shenyang Pharmaceutical University
1 shared publication- Guo-Yu Li
School of Pharmacy, Shihezi University , Shihezi , 832002 , China
1 shared publication
Latest Publications
- Open Access
- 16 April 2026
- Published by Frontiers Media SA in Frontiers in Gastroenterology
- Vol. 5, 1754027
Primary prevention in liver cirrhosis patients with esophageal varicesa: a systematic review and network meta-analysis
Objective: To compare the efficacy and safety of different primary preventive measures for esophageal variceal bleeding using a network meta-analysis. Methods: Randomized controlled trials (RCTs) on primary prevention were retrieved from PubMed, Cochrane Library, Embase, and Web of Science. Primary outcomes were the incidence of variceal bleeding, all-cause mortality, All-Cause Bleeding and Bleeding-Related Mortality. Secondary outcomes included adverse events and other decompensation events. Study quality was assessed with the Cochrane Risk of Bias tool. Data were analyzed using Revman 5.4 and Stata 16.0. Results: A total of 50 RCTs (6510 patients) evaluating 16 interventions were included. For reducing bleeding incidence, the combinations Midodrine + Propranolol (Mido+PPL), Carvedilol + Endoscopic Variceal Band Ligation (Carv+EVBL), and Fuzheng Huayu Capsule + Propranolol (FZHYJN+PPL) were superior. For lower all-cause mortality, Carv+EVBL, Mido+PPL, and Nadolol + Isosorbide Mononitrate (Nado+ISMN) were favorable. Carv+EVBL, EVBL, and Endoscopic Injection Sclerotherapy (EIS) were better for reducing bleeding-related mortality. Regarding safety, Mido+PPL, Nadolol (Nado), and Carvedilol (Carv) had fewer general adverse events, while Isosorbide Mononitrate (ISMN), Mido+PPL, and Carv had lower rates of other decompensation events. Conclusion: Based on low-certainty evidence, Mido+PPL demonstrated a favorable balance of efficacy and safety and is recommended as a preferred option. Mido+PPL, Carv+EVBL, and FZHYJN+PPL are recommended for primary prophylaxis in cirrhosis. For Child-Pugh A/B patients, Mido+PPL, Carv+EVBL, and FZHYJN+PPL are suggested, with EVBL as an alternative for those intolerant to drugs. EVBL may be considered for Child-Pugh C patients. Mido+PPL is recommended for prophylaxis within one year, FZHYJN+PPL for up to two years, and Carvedilol (alone or with EVBL) for long-term management beyond two years. Carvedilol and Propranolol showed superior net clinical benefit over Nadolol and Timolol. Although Nadolol (alone or with ISMN) may reduce mortality, its higher adverse event rate precludes it as a first-line strategy. FZHYJN, while effective, may increase the risk of other decompensation events.
- 16 April 2026
- Published by Frontiers Media SA in Frontiers in Gastroenterology
- Vol. 5, 1754027
Open AccessPrimary prevention in liver cirrhosis patients with esophageal varicesa: a systematic review and network meta-analysis
Objective: To compare the efficacy and safety of different primary preventive measures for esophageal variceal bleeding using a network meta-analysis. Methods: Randomized controlled trials (RCTs) on primary prevention were retrieved from PubMed, Cochrane Library, Embase, and Web of Science. Primary outcomes were the incidence of variceal bleeding, all-cause mortality, All-Cause Bleeding and Bleeding-Related Mortality. Secondary outcomes included adverse events and other decompensation events. Study quality was assessed with the Cochrane Risk of Bias tool. Data were analyzed using Revman 5.4 and Stata 16.0. Results: A total of 50 RCTs (6510 patients) evaluating 16 interventions were included. For reducing bleeding incidence, the combinations Midodrine + Propranolol (Mido+PPL), Carvedilol + Endoscopic Variceal Band Ligation (Carv+EVBL), and Fuzheng Huayu Capsule + Propranolol (FZHYJN+PPL) were superior. For lower all-cause mortality, Carv+EVBL, Mido+PPL, and Nadolol + Isosorbide Mononitrate (Nado+ISMN) were favorable. Carv+EVBL, EVBL, and Endoscopic Injection Sclerotherapy (EIS) were better for reducing bleeding-related mortality. Regarding safety, Mido+PPL, Nadolol (Nado), and Carvedilol (Carv) had fewer general adverse events, while Isosorbide Mononitrate (ISMN), Mido+PPL, and Carv had lower rates of other decompensation events. Conclusion: Based on low-certainty evidence, Mido+PPL demonstrated a favorable balance of efficacy and safety and is recommended as a preferred option. Mido+PPL, Carv+EVBL, and FZHYJN+PPL are recommended for primary prophylaxis in cirrhosis. For Child-Pugh A/B patients, Mido+PPL, Carv+EVBL, and FZHYJN+PPL are suggested, with EVBL as an alternative for those intolerant to drugs. EVBL may be considered for Child-Pugh C patients. Mido+PPL is recommended for prophylaxis within one year, FZHYJN+PPL for up to two years, and Carvedilol (alone or with EVBL) for long-term management beyond two years. Carvedilol and Propranolol showed superior net clinical benefit over Nadolol and Timolol. Although Nadolol (alone or with ISMN) may reduce mortality, its higher adverse event rate precludes it as a first-line strategy. FZHYJN, while effective, may increase the risk of other decompensation events.
- 18 December 2023
- Published by Walter de Gruyter GmbH in International Journal of Food Engineering
- Vol. 20 (1) , 51-61
Probiotic set-yogurt fortified with cranberry fruit powder: physicochemical properties and health effect on ulcerative colitis in mice
The aim of the study was to investigate the effect of cranberry fruit powder (CFP) on the physicochemical and bioactive properties of yogurt. The addition of CFP before fermentation enhanced the amount of total flavonoid, proanthocyanidin, antioxidant capacity and elastic modulus of yogurt compared with the control. In the experiment of ulcerative colitis (UC) in mice, the levels of TNF-α, IL-6, and IL-1β were statistically lower in the CFPY group than that of DSS group. Moreover, the histological lesions of UC mice were significantly ameliorated in the CFPY group. The pH value decreased significantly, but the sugar content, water holding capacity, susceptibility to syneresis improved a little during storage at 4 °C. The bacterial counts were more than the minimum recommended daily dose (6 log CFU/g) in CFP yogurt. The findings suggest that addition of CFP into yogurt is a promising option of producing novel yogurts with nutrition value and bioactivity.
- 18 December 2023
- Published by Walter de Gruyter GmbH in International Journal of Food Engineering
- Vol. 20 (1) , 51-61
Probiotic set-yogurt fortified with cranberry fruit powder: physicochemical properties and health effect on ulcerative colitis in mice
The aim of the study was to investigate the effect of cranberry fruit powder (CFP) on the physicochemical and bioactive properties of yogurt. The addition of CFP before fermentation enhanced the amount of total flavonoid, proanthocyanidin, antioxidant capacity and elastic modulus of yogurt compared with the control. In the experiment of ulcerative colitis (UC) in mice, the levels of TNF-α, IL-6, and IL-1β were statistically lower in the CFPY group than that of DSS group. Moreover, the histological lesions of UC mice were significantly ameliorated in the CFPY group. The pH value decreased significantly, but the sugar content, water holding capacity, susceptibility to syneresis improved a little during storage at 4 °C. The bacterial counts were more than the minimum recommended daily dose (6 log CFU/g) in CFP yogurt. The findings suggest that addition of CFP into yogurt is a promising option of producing novel yogurts with nutrition value and bioactivity.
- Open Access
- 7 November 2023
- Published by Spandidos Publications in Oncology Letters
- Vol. 27 (1) , 1-10
Selection of breast cancer subtypes to improve benefits of intensive dose‑dense chemotherapy: A systematic meta‑analysis
Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of cancer mortality among women worldwide. A large number of patients experience recurrence and BC‑associated mortality following adjuvant chemotherapy. The present study aimed to determine the most suitable pathological subtype of BC to benefit from intensive dose‑dense (DD) chemotherapy. A total of four electronic databases were searched from inception up to March 10, 2023. Randomized controlled trials (RCTs) and retrospective studies comparing DD chemotherapy with standard chemotherapy in patients with BC were included. Pairwise random effects and network meta‑analyses were performed to summarize efficacy and safety outcomes. A total of 27 original studies including 27,580 patients with BC were included. In terms of efficacy, the present study evaluated overall survival, disease‑free survival, event‑free survival, recurrence‑free survival, pathological complete response and objective remission rate. Significant differences were identified in overall, hormone receptor+ (HR+) and HR‑ subgroups. Furthermore, from the network analysis, the HR+ and Her2‑ subgroups had the highest ranking, and these findings suggested that HR+/Her2‑ patients with BC should adhere to a treatment strategy including intensive DD chemotherapy, which is also characterized by an acceptable safety profile. In conclusion, patients with HR+ and Her2‑ BC were revealed to be the most suitable pathological type and are most likely to benefit from intense DD chemotherapy. The present study was registered with PROSPERO, CRD2022420351567.
- 7 November 2023
- Published by Spandidos Publications in Oncology Letters
- Vol. 27 (1) , 1-10
Open AccessSelection of breast cancer subtypes to improve benefits of intensive dose‑dense chemotherapy: A systematic meta‑analysis
Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of cancer mortality among women worldwide. A large number of patients experience recurrence and BC‑associated mortality following adjuvant chemotherapy. The present study aimed to determine the most suitable pathological subtype of BC to benefit from intensive dose‑dense (DD) chemotherapy. A total of four electronic databases were searched from inception up to March 10, 2023. Randomized controlled trials (RCTs) and retrospective studies comparing DD chemotherapy with standard chemotherapy in patients with BC were included. Pairwise random effects and network meta‑analyses were performed to summarize efficacy and safety outcomes. A total of 27 original studies including 27,580 patients with BC were included. In terms of efficacy, the present study evaluated overall survival, disease‑free survival, event‑free survival, recurrence‑free survival, pathological complete response and objective remission rate. Significant differences were identified in overall, hormone receptor+ (HR+) and HR‑ subgroups. Furthermore, from the network analysis, the HR+ and Her2‑ subgroups had the highest ranking, and these findings suggested that HR+/Her2‑ patients with BC should adhere to a treatment strategy including intensive DD chemotherapy, which is also characterized by an acceptable safety profile. In conclusion, patients with HR+ and Her2‑ BC were revealed to be the most suitable pathological type and are most likely to benefit from intense DD chemotherapy. The present study was registered with PROSPERO, CRD2022420351567.
- 3 April 2023
- Published by Taylor & Francis in Journal of Asian Natural Products Research
- Vol. 25 (10) , 983-991
An efficient method for identifying natural common homoisoflavonoid by1H-NMR
Homoisoflavone contains 16 carbon atoms in the skeleton. The homoisoflavonoid skeleton from natural products can be roughly divided into 13 kinds, among which 5 kinds of common skeletons contain a large amount of compounds and 8 kinds of abnormal skeletons comprise a small amount of compounds. In this article, the structure identification experience of homoisoflavonoids found in Caesalpinia mimosoides was used as references and an efficient 1H NMR spectroscopic method for identifying homoisoflavonoid structure has been established. Using the chemical shift differences of H-2, 3, 4 and 9, the common natural homoisoflavonoids can be quickly and conveniently determined.
- 3 April 2023
- Published by Taylor & Francis in Journal of Asian Natural Products Research
- Vol. 25 (10) , 983-991
An efficient method for identifying natural common homoisoflavonoid by1H-NMR
Homoisoflavone contains 16 carbon atoms in the skeleton. The homoisoflavonoid skeleton from natural products can be roughly divided into 13 kinds, among which 5 kinds of common skeletons contain a large amount of compounds and 8 kinds of abnormal skeletons comprise a small amount of compounds. In this article, the structure identification experience of homoisoflavonoids found in Caesalpinia mimosoides was used as references and an efficient 1H NMR spectroscopic method for identifying homoisoflavonoid structure has been established. Using the chemical shift differences of H-2, 3, 4 and 9, the common natural homoisoflavonoids can be quickly and conveniently determined.
- 11 August 2022
- Published by Elsevier in Phytochemistry
- Vol. 203, 113372
Euphorfiatnoids A−I: Diterpenoids from the roots of Euphorbia fischeriana with cytotoxic effects
- 11 August 2022
- Published by Elsevier in Phytochemistry
- Vol. 203, 113372
Euphorfiatnoids A−I: Diterpenoids from the roots of Euphorbia fischeriana with cytotoxic effects
- 1 June 2018
- Published by Elsevier in Journal of Functional Foods
- Vol. 45, 471-479
Dietary functional flavonoids as natural hepatoprotective agents against acute liver injury from hop (Humulus lupulus L.)
- 1 June 2018
- Published by Elsevier in Journal of Functional Foods
- Vol. 45, 471-479
Dietary functional flavonoids as natural hepatoprotective agents against acute liver injury from hop (Humulus lupulus L.)
- Open Access
- 4 May 2012
- Published by Springer Nature in Journal of Inflammation
- Vol. 9 (1) , 16
Hepatoprotective effect of Matrine salvianolic acid B salt on Carbon Tetrachloride-Induced Hepatic Fibrosis
The aim of this study was to investigate the hepatoprotective effect of Matrine salvianolic acid B salt on carbon tetrachloride (CCl4)-induced hepatic fibrosis in rats. Salvianolic acid B and Matrine has long been used to treat liver fibrosis. Matrine salvianolic acid B salt is a new compound containing Salvianolic acid B and Matrine. Hepatic fibrosis induced by CCl4 was studied in animal models using Wistar rats. Organ coefficient, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), hexadecenoic acid (HA), laminin (LN), hydroxyproline (Hyp), and glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (SOD) in liver tissues were measured, respectively. Histopathological changes in the livers were studied by hematoxylin-eosin (H&E) staining and Masson Trichrome (MT) examination. The expression of transforming growth factor-β1 (TGF-β1) and α-smooth muscle actin (α-SMA) was observed by immunohistochemical analysis. A significant reduction in serum levels of AST, ALT, HA, LN and Hyp was observed in the Matrine salvianolic acid B salt treated groups, suggesting that the salt had hepatoprotective effects. The depletion of GSH and SOD, as well as MDA accumulation in liver tissues was suppressed by Matrine salvianolic acid B salt too. The expression of TGF-β1 and α-SMA measured by immunohistology was significantly reduced by Matrine salvianolic acid B salt in a dose-dependent manner. Matrine salvianolic acid B salt treatment attenuated the necro-inflammation and fibrogenesis induced by CCl4 injection, and thus it is promising as a therapeutic anti-fibrotic agent against hepatic fibrosis.
- 4 May 2012
- Published by Springer Nature in Journal of Inflammation
- Vol. 9 (1) , 16
Open AccessHepatoprotective effect of Matrine salvianolic acid B salt on Carbon Tetrachloride-Induced Hepatic Fibrosis
The aim of this study was to investigate the hepatoprotective effect of Matrine salvianolic acid B salt on carbon tetrachloride (CCl4)-induced hepatic fibrosis in rats. Salvianolic acid B and Matrine has long been used to treat liver fibrosis. Matrine salvianolic acid B salt is a new compound containing Salvianolic acid B and Matrine. Hepatic fibrosis induced by CCl4 was studied in animal models using Wistar rats. Organ coefficient, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), hexadecenoic acid (HA), laminin (LN), hydroxyproline (Hyp), and glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (SOD) in liver tissues were measured, respectively. Histopathological changes in the livers were studied by hematoxylin-eosin (H&E) staining and Masson Trichrome (MT) examination. The expression of transforming growth factor-β1 (TGF-β1) and α-smooth muscle actin (α-SMA) was observed by immunohistochemical analysis. A significant reduction in serum levels of AST, ALT, HA, LN and Hyp was observed in the Matrine salvianolic acid B salt treated groups, suggesting that the salt had hepatoprotective effects. The depletion of GSH and SOD, as well as MDA accumulation in liver tissues was suppressed by Matrine salvianolic acid B salt too. The expression of TGF-β1 and α-SMA measured by immunohistology was significantly reduced by Matrine salvianolic acid B salt in a dose-dependent manner. Matrine salvianolic acid B salt treatment attenuated the necro-inflammation and fibrogenesis induced by CCl4 injection, and thus it is promising as a therapeutic anti-fibrotic agent against hepatic fibrosis.